These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22525314)

  • 1. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
    Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
    Jansen K; Heirbaut L; Verkerk R; Cheng JD; Joossens J; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    J Med Chem; 2014 Apr; 57(7):3053-74. PubMed ID: 24617858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.
    Tsai TY; Yeh TK; Chen X; Hsu T; Jao YC; Huang CH; Song JS; Huang YC; Chien CH; Chiu JH; Yen SC; Tang HK; Chao YS; Jiaang WT
    J Med Chem; 2010 Sep; 53(18):6572-83. PubMed ID: 20718420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
    Tran T; Quan C; Edosada CY; Mayeda M; Wiesmann C; Sutherlin D; Wolf BB
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1438-42. PubMed ID: 17174090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.
    Jansen K; Heirbaut L; Cheng JD; Joossens J; Ryabtsova O; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    ACS Med Chem Lett; 2013 May; 4(5):491-6. PubMed ID: 24900696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.
    Poplawski SE; Lai JH; Li Y; Jin Z; Liu Y; Wu W; Wu Y; Zhou Y; Sudmeier JL; Sanford DG; Bachovchin WW
    J Med Chem; 2013 May; 56(9):3467-77. PubMed ID: 23594271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
    Chen SJ; Jiaang WT
    Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.
    Edosada CY; Quan C; Wiesmann C; Tran T; Sutherlin D; Reynolds M; Elliott JM; Raab H; Fairbrother W; Wolf BB
    J Biol Chem; 2006 Mar; 281(11):7437-44. PubMed ID: 16410248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
    Meadows SA; Edosada CY; Mayeda M; Tran T; Quan C; Raab H; Wiesmann C; Wolf BB
    Biochemistry; 2007 Apr; 46(15):4598-605. PubMed ID: 17381073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects.
    Cho JM; Yang EH; Quan W; Nam EH; Cheon HG
    Sci Rep; 2020 Dec; 10(1):21280. PubMed ID: 33277568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein α.
    Plescia J; De Cesco S; Patrascu MB; Kurian J; Di Trani J; Dufresne C; Wahba AS; Janmamode N; Mittermaier AK; Moitessier N
    J Med Chem; 2019 Sep; 62(17):7874-7884. PubMed ID: 31393718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.
    Bracke A; Van Elzen R; Van Der Veken P; Augustyns K; De Meester I; Lambeir AM
    Clin Chim Acta; 2019 Aug; 495():154-160. PubMed ID: 30981844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.
    Rosenblum JS; Kozarich JW
    Curr Opin Chem Biol; 2003 Aug; 7(4):496-504. PubMed ID: 12941425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.
    Jackson KW; Christiansen VJ; Yadav VR; Silasi-Mansat R; Lupu F; Awasthi V; Zhang RR; McKee PA
    Neoplasia; 2015 Jan; 17(1):43-54. PubMed ID: 25622898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.
    Jung HJ; Nam EH; Park JY; Ghosh P; Kim IS
    Bioorg Med Chem Lett; 2021 Apr; 37():127846. PubMed ID: 33571650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
    Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
    J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.
    Ospelt C; Mertens JC; Jüngel A; Brentano F; Maciejewska-Rodriguez H; Huber LC; Hemmatazad H; Wüest T; Knuth A; Gay RE; Michel BA; Gay S; Renner C; Bauer S
    Arthritis Rheum; 2010 May; 62(5):1224-35. PubMed ID: 20155839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.
    Christiansen VJ; Jackson KW; Lee KN; Downs TD; McKee PA
    Neoplasia; 2013 Apr; 15(4):348-58. PubMed ID: 23555181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.
    Slania SL; Das D; Lisok A; Du Y; Jiang Z; Mease RC; Rowe SP; Nimmagadda S; Yang X; Pomper MG
    J Med Chem; 2021 Apr; 64(7):4059-4070. PubMed ID: 33730493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.